Barely Significant
← all excerpts

Reducing the Burden of Heart Failure in Japan With Dapagliflozin　- A Cost Offset Model (IMPLICATION HF).

Circ Rep · 2025 · PMC12148354 · PMID 40497119

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

an increasing trendno p-value reported
The total annual cost (hHF+CV death) showed an increasing trend, costing approximately JPY374.1 billion with HF treatment without dapagliflozin in 2040.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.